Price
$1.94
Increased by +2.65%
Dollar Volume
11.35 M
ADR%
8.31
Earnings Report Date (estimate)
Oct 27, 22 (-0.01)
Market Cap.
783.43 M
Shares Float
372.04 M
Shares Outstanding
403.83 M
Beta
1.79
Price / Earnings
-34.64
BPR
184.23
20D Range
1.43 2.13
50D Range
1.12 2.13
200D Range
1.04 3.23
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Oct 27, 22 -0.01
Increased by +66.67%
-0.06
Increased by +83.33%
Aug 3, 22 -0.18
Decreased by -1000.00%
-0.06
Decreased by -200.00%
May 4, 22 -0.08
Decreased by -1.84 K%
-0.02
Decreased by -300.00%
Mar 1, 22 0.04
Increased by +300.00%
-0.02
Increased by +300.00%
Nov 3, 21 -0.03
Decreased by -50.00%
-0.04
Increased by +25.00%
Aug 5, 21 0.02
Increased by +100.00%
-0.03
Increased by +166.67%
Apr 29, 21 -0.00
Increased by +93.13%
-0.05
Increased by +91.76%
Feb 25, 21 0.01
Decreased by -50.00%
-0.01
Increased by +200.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 89.88 M
Decreased by -36.72%
-5.14 M
Increased by +60.92%
Decreased by -5.72%
Increased by +38.23%
Jun 30, 22 94.44 M
Decreased by -38.87%
-69.96 M
Decreased by -995.95%
Decreased by -74.07%
Decreased by -1.57 K%
Mar 31, 22 94.63 M
Decreased by -33.44%
-31.56 M
Decreased by -1.84 K%
Decreased by -33.35%
Decreased by -2.82 K%
Dec 31, 21 144.49 M
Decreased by -13.61%
14.70 M
Increased by +198.38%
Increased by +10.17%
Increased by +245.38%
Sep 30, 21 142.04 M
Decreased by -9.24%
-13.15 M
Decreased by -93.74%
Decreased by -9.26%
Decreased by -113.46%
Jun 30, 21 154.49 M
Increased by +14.17%
7.81 M
Increased by +76.85%
Increased by +5.05%
Increased by +54.91%
Mar 31, 21 142.17 M
Decreased by -8.27%
-1.63 M
Increased by +92.09%
Decreased by -1.14%
Increased by +91.38%
Dec 31, 20 167.25 M
Increased by +16.73%
4.93 M
Decreased by -30.31%
Increased by +2.95%
Decreased by -40.30%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.